Centogene NV CNTG, +43.15% ,, which specializes genetic diagnostics for diseases that are rare, saw its shares jump 50% in premarket trade Tuesday, after the company announced it had formed a joint venture Lifera with a biopharmaceutical firm owned by Saudi Arabia’s Public Investment Fund. Centogene said that the JV will bring $30 million to the company and focus on multiomic testing for patients, health systems and biopharmaceutical clients in Saudi Arabia and the Gulf Cooperation Council countries. The $30 million investment is in the form a mandatory convertible debt with a term of six months and a conversion rate of $2.20 for each share of Centogene’s common stock.